...
bmrn-img

Biomarin Pharmaceutical Inc, Common Stock

BMRN

NSQ

$65.66

+$0.66

(1.02%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$12.33B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
38.9699
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.86M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.31
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$61.15 L
$99.25 H
$65.66

About Biomarin Pharmaceutical Inc, Common Stock

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameBMRNSectorS&P500
1-Week Return-0.53%-2.12%-3%
1-Month Return4.96%-3.42%-0.73%
3-Month Return-7.12%-11.13%2.87%
6-Month Return-22.49%-5.74%7.17%
1-Year Return-29.14%3.97%25.31%
3-Year Return-24.43%1.05%28.38%
5-Year Return-22.53%34.37%81.89%
10-Year Return-29.25%97.88%183.27%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue1.70B1.86B1.85B2.10B2.42B[{"date":"2019-12-31","value":70.44,"profit":true},{"date":"2020-12-31","value":76.9,"profit":true},{"date":"2021-12-31","value":76.32,"profit":true},{"date":"2022-12-31","value":86.64,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue359.47M524.27M470.51M483.67M577.07M[{"date":"2019-12-31","value":62.29,"profit":true},{"date":"2020-12-31","value":90.85,"profit":true},{"date":"2021-12-31","value":81.54,"profit":true},{"date":"2022-12-31","value":83.82,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit1.34B1.34B1.38B1.61B1.84B[{"date":"2019-12-31","value":72.99,"profit":true},{"date":"2020-12-31","value":72.53,"profit":true},{"date":"2021-12-31","value":74.68,"profit":true},{"date":"2022-12-31","value":87.53,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin78.91%71.82%74.52%76.92%76.15%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":91.02,"profit":true},{"date":"2021-12-31","value":94.44,"profit":true},{"date":"2022-12-31","value":97.49,"profit":true},{"date":"2023-12-31","value":96.5,"profit":true}]
Operating Expenses1.47B1.43B1.46B1.57B1.75B[{"date":"2019-12-31","value":84.18,"profit":true},{"date":"2020-12-31","value":82.03,"profit":true},{"date":"2021-12-31","value":83.5,"profit":true},{"date":"2022-12-31","value":89.95,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(125.46M)(96.26M)(60.01M)57.55M194.44M[{"date":"2019-12-31","value":-64.52,"profit":false},{"date":"2020-12-31","value":-49.51,"profit":false},{"date":"2021-12-31","value":-30.86,"profit":false},{"date":"2022-12-31","value":29.6,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense29.93M(18.26M)(20.19M)2.08M28.26M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-60.99,"profit":false},{"date":"2021-12-31","value":-67.46,"profit":false},{"date":"2022-12-31","value":6.94,"profit":true},{"date":"2023-12-31","value":94.42,"profit":true}]
Pre-Tax Income(94.81M)(42.32M)(75.35M)149.58M188.56M[{"date":"2019-12-31","value":-50.28,"profit":false},{"date":"2020-12-31","value":-22.44,"profit":false},{"date":"2021-12-31","value":-39.96,"profit":false},{"date":"2022-12-31","value":79.32,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income Taxes(70.96M)(901.42M)(11.27M)8.02M20.92M[{"date":"2019-12-31","value":-339.24,"profit":false},{"date":"2020-12-31","value":-4309.31,"profit":false},{"date":"2021-12-31","value":-53.88,"profit":false},{"date":"2022-12-31","value":38.32,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(23.85M)859.10M(64.08M)141.56M167.65M[{"date":"2019-12-31","value":-2.78,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-7.46,"profit":false},{"date":"2022-12-31","value":16.48,"profit":true},{"date":"2023-12-31","value":19.51,"profit":true}]
Income From Continuous Operations(23.85M)859.10M(64.08M)141.56M147.02M[{"date":"2019-12-31","value":-2.78,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-7.46,"profit":false},{"date":"2022-12-31","value":16.48,"profit":true},{"date":"2023-12-31","value":17.11,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(23.85M)854.03M(64.08M)141.56M167.65M[{"date":"2019-12-31","value":-2.79,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-7.5,"profit":false},{"date":"2022-12-31","value":16.58,"profit":true},{"date":"2023-12-31","value":19.63,"profit":true}]
EPS (Diluted)(0.15)4.55(0.36)0.290.95[{"date":"2019-12-31","value":-3.3,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-7.91,"profit":false},{"date":"2022-12-31","value":6.35,"profit":true},{"date":"2023-12-31","value":20.88,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

BMRN
Cash Ratio 1.30
Current Ratio 4.27
Quick Ratio 2.62

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BMRN
ROA (LTM) 3.00%
ROE (LTM) 6.25%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BMRN
Debt Ratio Lower is generally better. Negative is bad. 0.21
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.79

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BMRN
Trailing PE 39.16
Forward PE 16.84
P/S (TTM) 4.50
P/B 2.29
Price/FCF 62
EV/R 4.38
EV/Ebitda 23.80
PEG 0.40

FAQs

What is Biomarin Pharmaceutical Inc share price today?

Biomarin Pharmaceutical Inc (BMRN) share price today is $65.66

Can Indians buy Biomarin Pharmaceutical Inc shares?

Yes, Indians can buy shares of Biomarin Pharmaceutical Inc (BMRN) on Vested. To buy Biomarin Pharmaceutical Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BMRN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Biomarin Pharmaceutical Inc be purchased?

Yes, you can purchase fractional shares of Biomarin Pharmaceutical Inc (BMRN) via the Vested app. You can start investing in Biomarin Pharmaceutical Inc (BMRN) with a minimum investment of $1.

How to invest in Biomarin Pharmaceutical Inc shares from India?

You can invest in shares of Biomarin Pharmaceutical Inc (BMRN) via Vested in three simple steps:

  • Click on Sign Up or Invest in BMRN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Biomarin Pharmaceutical Inc shares
What is Biomarin Pharmaceutical Inc 52-week high and low stock price?

The 52-week high price of Biomarin Pharmaceutical Inc (BMRN) is $99.25. The 52-week low price of Biomarin Pharmaceutical Inc (BMRN) is $61.15.

What is Biomarin Pharmaceutical Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Biomarin Pharmaceutical Inc (BMRN) is 38.9699

What is Biomarin Pharmaceutical Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Biomarin Pharmaceutical Inc (BMRN) is 2.29

What is Biomarin Pharmaceutical Inc dividend yield?

The dividend yield of Biomarin Pharmaceutical Inc (BMRN) is 0.00%

What is the Market Cap of Biomarin Pharmaceutical Inc?

The market capitalization of Biomarin Pharmaceutical Inc (BMRN) is $12.33B

What is Biomarin Pharmaceutical Inc’s stock symbol?

The stock symbol (or ticker) of Biomarin Pharmaceutical Inc is BMRN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top